Reduction in Health Care-Related Costs after Initiation of Treatment with a Prescription Digital Therapeutic for Chronic Insomnia: Two-Year Follow up Analysis of Health Care Claims Data


Forma F1, Knight T2, Thorndike F1, Xiong X1, Baik R2, Velez F1, Maricich Y1, Malone D3
1Pear Therapeutics, Inc., Boston, MA, USA, 2Covance Market Access Services Inc., Gaithersburg, MD, USA, 3Strategic Therapeutics, LLC, Tucson, AZ, USA

Objective: The objective of this study was to evaluate the 2-year effectiveness of the first FDA-authorized prescription digital therapeutic (PDT) for adults with chronic insomnia that delivers evidence-based treatment (Somryst®). PDTs are software-based disease treatments evaluated for safety and effectiveness in randomized clinical trials, and authorized by the US Food and Drug Administration (FDA) to treat disease with approved directions for use (label).

Methods: A pre/post multi-payer analysis of claims data was conducted, comparing two-year pre- and post-index healthcare resource utilization (HCRU) in an all-comer population of patients with self-identified sleep problems across the United States who activated the PDT between February 1, 2012 and December 31, 2018 (Index). HCRU categories assessed were: hospitalizations, treat-and-release emergency department (ED) visits, ambulatory surgical center (ASC) visits, hospital outpatient department (HOPD) visits, office visits, number of sleep medication prescriptions, and associated health care costs. Costs were estimated by multiplying HCRU by published average costs for each medical resource.

Results: 252 patients initiating the PDT were analyzed (mean age 54.2 years, 57.5% female). Compared to the pre-index period, post-index events were reduced for ED (-56.2%; P=0.001), hospitalizations (-20.9%; P=0.4), sleep medication use (-8.9%; P=0. 0.377), HOPD (-8.3%; P=0.522), and ASC (-6.7%; P=0.695). Post-index events were slightly increased for office visits (+0.7%; P=0.891). Total estimated two-year cost savings associated with the reduced rates of all services except office visits was $494,634, or $1,963 per patient.

Conclusion: In a real-world cohort of patients with self-identified sleep problems, treatment for 9 weeks with a PDT delivering digital CBT-I was associated with clinically meaningful net reductions in health-related services and associated costs with 2-year follow-up.

Disclaimer: On 12/16/21, ISPOR granted permission via email to F. Velez to use the product name Somryst in the abstract, due to a lack of a generic name for the product.

Conference/Value in Health Info

2022-05, ISPOR 2022, Washington, DC, USA

Value in Health, Volume 25, Issue 6, S1 (June 2022)




Economic Evaluation, Health Policy & Regulatory, Study Approaches

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis, Electronic Medical & Health Records, Insurance Systems & National Health Care


Medical Devices, Systemic Disorders/Conditions

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now